

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 4 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records  
NEWS 5 MAY 11 KOREPAT updates resume  
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced  
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and  
USPATFULL/USPAT2  
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAplus  
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 13 JUL 14 FSTA enhanced with Japanese patents  
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 15 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 17 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes  
NEWS 18 SEP 11 CA/CAplus enhanced with more pre-1907 records  
NEWS 19 SEP 21 CA/CAplus fields enhanced with simultaneous left and right  
truncation

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:40:44 ON 23 SEP 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:40:53 ON 23 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2  
DICTIONARY FILE UPDATES: 21 SEP 2006 HIGHEST RN 908228-18-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10863995a.str



chain nodes :

10

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

11

chain bonds :

4-11 6-10

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

2-7 4-11 6-10 7-8

exact bonds :

3-9 8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :


G1:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS  
11:CLASS

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



G1 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam  
SAMPLE SEARCH INITIATED 09:41:08 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 25 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 200 TO 800  
PROJECTED ANSWERS: 200 TO 800

L2 25 SEA SSS SAM L1

=> s l1 full  
FULL SEARCH INITIATED 09:41:14 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 515 TO ITERATE

100.0% PROCESSED 515 ITERATIONS 492 ANSWERS  
SEARCH TIME: 00.00.01

L3 492 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
166.94 167.15

FILE 'CAPLUS' ENTERED AT 09:41:20 ON 23 SEP 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Sep 2006 VOL 145 ISS 14  
FILE LAST UPDATED: 22 Sep 2006 (20060922/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s 13  
L4            14 L3

=> d 14 ibib hitstr abs 1-14


L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:16623 CAPLUS  
DOCUMENT NUMBER: 144:184021  
TITLE: Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists  
AUTHOR(S): Baxter, Andrew; Cooper, Anne; Kinchin, Elizabeth; Moakes, Kerry; Unitt, John; Wallace, Alan  
CORPORATE SOURCE: AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK  
SOURCE: Bioorg. Med. Chem. Lett. (2006), 16(4), 960-963  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
IT 259100-40-8 259100-45-3 259100-69-1  
259100-74-8 259101-51-4 259101-52-5  
259101-53-6 259101-55-8 874963-36-7  
874963-40-3  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists)  
RN: 259100-40-8 CAPLUS  
CN: 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259100-45-3 CAPLUS  
CN Ethanol, 2-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-


(9CI) (CA INDEX NAME)



RN 259100-69-1 CAPLUS  
CN 1-Propanol, 3-[(2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino)-  
(9CI) (CA INDEX NAME)




RN 259100-74-8 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopentyl-5-(pentylthio)-  
(9CI) (CA INDEX NAME)



RN 259101-51-4 CAPLUS  
CN 1-Butanol, 2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-52-5 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-53-6 CAPLUS


CN 1-Butanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-55-8 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 874963-36-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N,N-diethyl-5-(pentylthio)- (9CI) (CA INDEX NAME)



RN 874963-40-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



IT 259100-39-5 259101-56-9


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)

(discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists)

RN 259100-39-5 CAPLUS


CN 1-Butanol, 2-[(2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-, (2R)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 259101-56-9 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)





AB A Hit-to-Lead optimization program was carried out on a high throughput screening hit, the thiazolo[4,5-d]pyrimidine (I), resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist II.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:547606 CAPLUS

DOCUMENT NUMBER: 143:78206

TITLE: Process for preparation of 5-difluorobenzylthio-7-aminothiazolo[4,5-d]pyrimidin-2(3H)-ones via protection and amination reactions.

INVENTOR(S): Butters, Michael; Wisedale, Richard; Thomson, Colin; Welham, Matthew James; Watts, Andrew

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056563	A2	20050623	WO 2004-GB5072	20041202
WO 2005056563	A3	20050825		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004296241	A1	20050623	AU 2004-296241	20041202

CA 2546719 AA 20050623 CA 2004-2546719 20041202  
 PRIORITY APPLN. INFO.: GB 2003-28243 A 20031205  
 WO 2004-GB5072 W 20041202


OTHER SOURCE(S): MARPAT 143:78206  
 IT 676345-23-6P 855476-56-1P 855476-57-2P  
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP  
 (Preparation)  
 (claimed compound; preparation of  
 difluorobenzylthioaminothiazolopyrimidinones  
 via protection and amination reactions)  
 RN 676345-23-6 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[{(2,3-difluorophenyl)methyl]thio]-7-  
 [[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI)  
 (CA INDEX NAME)



● Na


RN 855476-56-1 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[{(2,3-difluorophenyl)methyl]thio]-7-  
 [[(1R)-2-hydroxy-1-methylethyl]amino]-, monopotassium salt (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.



● K

RN 855476-57-2 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[{(2,3-difluorophenyl)methyl]thio]-7-  
 [[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monopotassium salt  
 (9CI) (CA INDEX NAME)



● K


IT 333742-48-6P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of difluorobenzylthioaminothiazolopyrimidinones via protection and amination reactions)


RN 333742-48-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. I [R1 = (substituted) carbocyclyl, alkyl, alkenyl, alkynyl, aryl, heteroaryl; R2, R3 = H, (substituted) alkyl, carbocyclyl, alkenyl, alkynyl], were prepared by treatment of precursors II (R1 as above; L = leaving group; Q = H) with a protecting reagent to give I; (R1, L as above; Q = protecting group), treatment of the latter with HNR2R3 (R2, R3 as above), and deprotection. Thus, 7-chloro-5-[[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2(3H)-one (preparation given) and p-TsOH in PhMe at 60° was treated with 3,4-dihydropyran

over 1 h and maintained at 60° for 2 h. The mixture was cooled, stirred with aqueous NaHCO<sub>3</sub> and then brine and the resulting solution was heated

with THF, Na<sub>2</sub>CO<sub>3</sub>, and D-alaninol followed by heating at 60° for 11.5 h and at 65° for 24 h to give 5-[(2,3-difluorophenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]-3-(tetrahydro-2H-pyran-2-yl)thiazolo[4,5-d]pyrimidin-2(3H)-one. The latter in MeCN/H<sub>2</sub>O/THF at 65° was treated with 1N HCl over 3 h to give 5-[(2,3-difluorophenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]-3-(tetrahydro-2H-pyran-2-yl)thiazolo[4,5-d]pyrimidin-2(3H)-one.

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:324167 CAPLUS  
 DOCUMENT NUMBER: 142:392432  
 TITLE: Preparation of new 2-substituted-4-aminothiazolo[4,5-d]pyrimidines and pteridinones useful as CX3CR1 chemokine receptor antagonists  
 INVENTOR(S): Nordvall, Gunnar; Rein, Tobias; Sohn, Daniel; Zemribo, Ronald  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 71 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033115	A1	20050414	WO 2004-SE1421	20041005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004278276	A1	20050414	AU 2004-278276	20041005
CA 2541533	AA	20050414	CA 2004-2541533	20041005
EP 1675862	A1	20060705	EP 2004-775512	20041005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:				
		SE 2003-2666	A	20031007
		SE 2003-2667	A	20031007
		WO 2004-SE1421	W	20041005

OTHER SOURCE(S): MARPAT 142:392432  
 IT 849942-83-2P 849942-86-5P 849942-88-7P,  
 (2R)-2-[[2-Amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-90-1P,  
 (R)-2-[[2-Amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849943-44-8P  
 , 5-[[2-(3-Chlorophenyl)ethyl]sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one  
 849943-49-3P, 5-[[2-(2-Bromophenyl)ethyl]sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-51-7P, 5-[(2,3-Difluorobenzyl)sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-52-8P, 5-(Benzylsulfinyl)-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

849943-55-1P, 5-[(2-Chlorobenzyl)sulfinyl]-7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-57-3P, 5-[(4-Chlorobenzyl)sulfinyl]-7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-59-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 849942-83-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(4-bromo-2-fluorophenyl)methyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-86-5 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-(4-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-88-7 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-(2-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-90-1 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-44-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(3-chlorophenyl)ethyl]sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-49-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(2-bromophenyl)ethyl]sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-51-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]sulfinyl]-1-7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-52-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-55-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2-chlorophenyl)methyl]sulfinyl]-7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-57-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[4-chlorophenyl)methyl]sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-59-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 259101-09-2, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 259101-69-4,

(2R)-2-[[2-Amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 463954-29-2,  
 (2R)-2-[[5-(Benzylthio)-2-bromo[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 463954-32-7, (2R)-2-[(2-Amino-5-mercaptop[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol  
 849943-27-7, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methylbutan-1-ol  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 259101-09-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-69-4 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-29-2 CAPLUS

CN 1-Pentanol, 2-[[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-32-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-27-7 CAPLUS

CN 1-Butanol, 2-[(2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-27-0P, [1-[(2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]cyclopentyl]methanol 849942-72-9P,

(2R)-2-[(2-Amino-5-(benzylsulfonyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol 849942-77-4P, (2R)-2-[(2-Amino-5-

(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-78-5P, (2R)-2-[(2-Amino-5-


(benzylsulfonyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-84-3P, (2R)-2-[(2-Amino-5-

mercapto[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-85-4P, (2R)-2-[(2-Amino-5-[(4-bromo-2-

fluorobenzyl)thio] [1,3]thiazolo[4,5-d]pyrimidin-7-yl] (methyl)amino]-4-methylpentan-1-ol 849942-87-6P, (2R)-2-[2-Amino-5-[(2-(4-bromophenyl)ethyl)thio] [1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-89-8P, (2R)-2-[2-Amino-5-[(2-(2-bromophenyl)ethyl)thio] [1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-10-8P, (2R)-2-[2-Chloro-5-[(2,3-difluorobenzyl)thio] [1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-11-9P, (2R)-2-[5-[(2,3-Difluorobenzyl)thio]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-13-1P, 5-[(2,3-Difluorobenzyl)sulfonyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-17-5P, (2R)-2-[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol 849943-18-6P, (2R)-2-[[5-(Benzylthio)-2-chloro[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol 849943-19-7P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol 849943-20-0P, 5-(Benzylthio)-7-[(1R)-1-(hydroxymethyl)butyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-21-1P, 5-(Benzylsulfonyl)-7-[(1R)-1-(hydroxymethyl)butyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-26-6P, (2R)-2-[[5-(Benzylthio)-2-chloro[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methylbutan-1-ol 849943-28-8P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methylbutan-1-ol 849943-30-2P, 5-(Benzylsulfonyl)-7-[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-32-4P, 5-(Benzylthio)-7-[(1R)-1-(hydroxymethyl)cyclopentyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-33-5P, 5-(Benzylsulfonyl)-7-[(1R)-1-(hydroxymethyl)cyclopentyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-45-9P, (2R)-2-[[2-Chloro-5-[(2-chloro-7-[(1R)-1-hydroxymethyl]-3-methylbutyl)amino] [1,3]thiazolo[4,5-d]pyrimidin-5-yldisulfanyl] [1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-46-0P, (2R)-2-[[5-[(7-[(1R)-1-Hydroxymethyl]-3-methylbutyl)amino]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-5-yldisulfanyl]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-47-1P 849943-48-2P, 5-[(2-(3-Chlorophenyl)ethyl)thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-50-6P, 5-[(2-(2-Bromophenyl)ethyl)thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-53-9P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-56-2P, 5-[(2-Chlorobenzyl)thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-58-4P, 5-[(4-Chlorobenzyl)thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino] [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 463954-27-0 CAPLUS


CN Cyclopantanemethanol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 849942-72-9 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-77-4 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-78-5 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl)methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-84-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]methylamino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-85-4 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(4-bromo-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-87-6 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-(4-bromophenyl)ethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849942-89-8 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-10-8 CAPLUS

CN 1-Pentanol, 2-[[2-chloro-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-11-9 CAPLUS

CN 1-Pentanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-13-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2,3-difluorophenyl)methyl]sulfonyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-17-5 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-18-6 CAPLUS

CN 1-Pentanol, 2-[[2-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-19-7 CAPLUS

CN 1-Pentanol, 2-[(2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-20-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(1R)-1-(hydroxymethyl)butyl]amino-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-21-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(1R)-1-(hydroxymethyl)butyl]amino-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-26-6 CAPLUS

CN 1-Butanol, 2-[(2-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-28-8 CAPLUS

CN 1-Butanol, 2-[(2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-30-2 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849943-32-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 849943-33-5 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 849943-45-9 CAPLUS

CN 1-Pentanol, 2,2'-[dithiobis[(2-chlorothiazolo[4,5-d]pyrimidine-5,7-diyl)imino]]bis[4-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-46-0 CAPLUS

CN 1-Pentanol, 2,2'-(dithiobis[(2-methoxythiazolo[4,5-d]pyrimidine-5,7-diyl)imino])bis[4-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-47-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5,5'-dithiobis[7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-48-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(3-chlorophenyl)ethyl]thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-50-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(2-bromophenyl)ethyl]thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-53-9 CAPLUS

CN 1-Pentanol, 2-[(2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-56-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2-chlorophenyl)methyl]thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-58-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(4-chlorophenyl)methyl]thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-11-2 849943-60-8 849943-61-9

RL: PRP (Properties)


(solubility comparison to ether analog; preparation of new  
2-substituted-4-amino-

thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor  
antagonists)

RN 463954-11-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[[(3-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-60-8 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-61-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[[(3-methoxyphenyl)methyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 849942-91-2P 849943-12-0P 849943-29-9P  
849943-54-0P


RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(solubility comparison to ether analog; preparation of new

2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 849942-91-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl)methylamino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-12-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 849943-29-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 849943-54-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB There are disclosed 2-substituted-4-aminothiazolo[4,5-d]pyrimidines and pteridinones (shown as I; variables defined below; e.g. 5-(benzyloxy)-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo [4,5-d]pyrimidin-2(3H)-one (shown as II)) and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compns. comprising them and their use in therapy. I are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis and pain. For I: A = 1,2-dihydro-2-oxo-3-R21pyrazine, 2-(R22R23N)thiazole, or 2-oxothiazoline; R1 and R2 = H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl or C3-7 saturated or partially unsatd. cycloalkyl; the latter 4 groups being optionally further substituted; R3 = C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl or C3-7 saturated or partially unsatd. cycloalkyl; X = O or S(O); R21 = H, CH2OR24, CH2NR24R25, CO2R24 or CONR24R25; R22 and R23 = H, C1-6-alkyl, C2-6-alkenyl or C3-7 saturated or partially unsatd. cycloalkyl; n = 0-2; R4-R20, R24, R25 = H or C1-6-alkyl; addnl. details are given in the claims. Methods of preparation are claimed and 49 example preps. are included. For example, II was prepared in 5 steps (88, 88, 90, 82 and 16 % yields) starting from (2R)-2-[(2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol and involving intermediates (2R)-2-[(2-chloro-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol, (2R)-2-[[5-[(2,3-difluorobenzyl)thio]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol, 5-[(2,3-difluorobenzyl)thio]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one and 5-[(2,3-difluorobenzyl)sulfonyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one. When tested in a ligand binding assay, the 49 examples of I gave Ki values of <10 μM, indicating that they are expected to show useful therapeutic activity. For example, II and 5-[(2,3-difluorobenzyl)sulfinyl]-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one gave Ki values of 44.6 and 38.0 nM resp. Representative solubility data are shown in which 8 examples of I have much greater solubility than the corresponding thioether analogs of other inventions.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:267340 CAPLUS

DOCUMENT NUMBER: 140:303689

TITLE: Preparation of 5-{{(2,3-difluorophenyl)methyl}thio}-7-{{(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist

INVENTOR(S): Bonnert, Roger Victor

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026880	A1	20040401	WO 2003-GB3998	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498762	AA	20040401	CA 2003-2498762	20030916
AU 2003267571	A1	20040408	AU 2003-267571	20030916
EP 1543013	A1	20050622	EP 2003-748263	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014844	A	20050809	BR 2003-14844	20030916
CN 1681826	A	20051012	CN 2003-822335	20030916
JP 2006503835	T2	20060202	JP 2004-537276	20030916
ZA 2005002272	A	20050919	ZA 2005-2272	20050317
NO 2005001892	A	20050617	NO 2005-1892	20050419
US 2006100221	A1	20060511	US 2005-528316	20051201
PRIORITY APPLN. INFO.:			GB 2002-21828	A 20020920
			WO 2003-GB3998	W 20030916

OTHER SOURCE(S): MARPAT 140:303689


IT 676345-22-5P 676345-23-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(multi-step preparation of 5-[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)


RN 676345-22-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]- (9CI) (CA INDEX NAME)



RN 676345-23-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

IT 259101-71-8P 676345-25-8P 676345-26-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (multi-step preparation of 5-[(2,3-difluorophenyl)methyl]thio-7-[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)


RN 259101-71-8 CAPPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 676345-25-8 CAPPLUS

CN 1,3-Propanediol, 2-[[2-chloro-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 676345-26-9 CAPPLUS

CN 1,3-Propanediol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compound I and its monosodium salt, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., were prepared in a multi-step process, starting from 4-amino-6-hydroxy-2-mercaptopurine and 2,3-difluorobenzyl bromide. The compound I showed IC<sub>50</sub> of < 10 μM against hCXCR2 binding. The latter was also tested in intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is claimed. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:267303 CAPLUS

DOCUMENT NUMBER: 140:303685

TITLE: Preparation of 5-[(2,3-difluorophenyl)methyl]thio)-7-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino)thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist

INVENTOR(S): Brough, Stephen John; McInally, Thomas

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026835	A1	20040401	WO 2003-GB4000	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				


CA 2498760	AA 20040401	CA 2003-2498760	20030916
AU 2003264765	A1 20040408	AU 2003-264765	20030916
EP 1542974	A1 20050622	EP 2003-797377	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003014843	A 20050809	BR 2003-14843	20030916
CN 1681787	A 20051012	CN 2003-822336	20030916
JP 2006503836	T2 20060202	JP 2004-537278	20030916
ZA 2005002267	A 20050919	ZA 2005-2267	20050317
US 2005272750	A1 20051208	US 2005-528270	20050317
NO 2005001893	A 20050617	NO 2005-1893	20050419
PRIORITY APPLN. INFO.:		GB 2002-21829	A 20020920
		WO 2003-GB4000	W 20030916
OTHER SOURCE(S):	MARPAT 140:303685		
IT 676345-69-0P			
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(multi-step preparation of 5-{{(2,3-difluorophenyl)methyl}thio}-7-{{(1S,2S)- 2-hydroxy-1-(hydroxymethyl)propyl}amino}thiazolo[4,5-d]pyrimidin-2(3H)- one as CXCR2 receptor antagonist)		
RN 676345-69-0 CAPLUS			
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-{{(2,3-difluorophenyl)methyl}thio}-7- {{(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl}amino}- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.



IT 676345-70-3P 676345-71-4P			
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)			
	(multi-step preparation of 5-{{(2,3-difluorophenyl)methyl}thio}-7-{{(1S,2S)- 2-hydroxy-1-(hydroxymethyl)propyl}amino}thiazolo[4,5-d]pyrimidin-2(3H)- one as CXCR2 receptor antagonist)		
RN 676345-70-3 CAPLUS			
CN 1,3-Butanediol, 2-[[2-amino-5-{{(2,3-difluorophenyl)methyl}thio}thiazolo[4, 5-d]pyrimidin-7-yl]amino]-, (2S,3S)- (9CI) (CA INDEX NAME)			


Absolute stereochemistry.



RN 676345-71-4 CAPLUS

CN 1,3-Butanediol, 2-[2-chloro-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compound I, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., was prepared in a 7-step process, starting from 4-amino-6-hydroxy-2-mercaptopurine and 2,3-difluorobenzyl bromide. The compound I showed IC<sub>50</sub> of < 10 μM against hCXCR2 binding. The latter was also tested in intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is claimed. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:814150 CAPLUS

DOCUMENT NUMBER: 137:325430


TITLE: Preparation of thiazolopyrimidines as modulators of

INVENTOR(S): chemokine receptor activity  
 Bonnert, Roger  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083693	A1	20021024	WO 2002-SE731	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385854	A1	20040204	EP 2002-724837	20020412
EP 1385854	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525972	T2	20040826	JP 2002-581448	20020412
AT 288919	E	20050215	AT 2002-724837	20020412
US 2004157853	A1	20040812	US 2003-474610	20031009
US 6949643	B2	20050927		
US 2006111569	A1	20060525	US 2005-225379 SE 2001-1322 WO 2002-SE731 US 2003-474610	20050912 A 20010412 W 20020412 A1 20031009
PRIORITY APPLN. INFO.:				

OTHER SOURCE(S): MARPAT 137:325430  
 IT 333742-48-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolopyrimidines as modulators of chemokine receptor activity)  
 RN 333742-48-6 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 333743-03-6P 473708-91-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of thiazolopyrimidines as modulators of chemokine receptor  
activity)

RN 333743-03-6 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-  
d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 473708-91-7 CAPLUS

CN 1-Propanol, 2-[[2-chloro-5-[[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-  
d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; A = II, III; R1 = cycloalkyl, alkyl, alkenyl, etc.; R2, R3 = H, cycloalkyl, alkyl, etc.; X = CH, CCN; Y = N, CR18; R18 = H, alkyl, Ph], useful for treating a chemokine mediated disease such as psoriasis, rheumatoid arthritis, and COPD, were prepared E.g., a 5-step synthesis of (1R)-IV, starting from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-d]pyrimidin-7(4H)-one and 2,3-difluorobenzyl bromide, was given. The compds. I were found to have IC50 values of < 10  $\mu$ M against CXCR2 receptor binding. They were also tested against chemokine GRO $\alpha$  (no data given).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2002:754394 CAPLUS  
 DOCUMENT NUMBER: 137:263057  
 TITLE: Preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists  
 INVENTOR(S): Hanson, Sverker; Nordvall, Gunnar  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076990	A1	20021003	WO 2002-SE599	20020326
WO 2002076990	C1	20021114		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002245005	A1	20021008	AU 2002-245005	20020326
EP 1377590	A1	20040107	EP 2002-713341	20020326


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 JP 2004524351 T2 20040812 JP 2002-576248 20020326  
 US 2004106628 A1 20040603 US 2003-472992 20030925  
 US 7067657 B2 20060627  
 PRIORITY APPLN. INFO.: SE 2001-1082 A 20010327  
 WO 2002-SE599 W 20020326

OTHER SOURCE(S): MARPAT 137:263057  
 IT 463953-89-1P 463953-90-4P 463953-91-5P  
 463953-92-6P 463953-93-7P 463953-94-8P  
 463953-95-9P 463953-96-0P 463953-97-1P  
 463953-98-2P 463953-99-3P 463954-00-9P  
 463954-01-0P 463954-02-1P 463954-03-2P  
 463954-04-3P 463954-05-4P 463954-06-5P  
 463954-07-6P 463954-08-7P 463954-09-8P  
 463954-10-1P 463954-11-2P 463954-12-3P  
 463954-13-4P 463954-14-5P 463954-15-6P  
 463954-16-7P 463954-17-8P 463954-18-9P  
 463954-19-0P 463954-20-3P 463954-21-4P  
 463954-22-5P 463954-23-6P 463954-24-7P  
 463954-25-8P 463954-26-9P 463954-27-0P  
 463954-28-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)


RN 463953-89-1 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl- (9CI) (CA INDEX NAME)



RN 463953-90-4 CAPLUS


CN 1-Hexanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 463953-91-5 CAPLUS

CN Acetamide, 2-[[7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-92-6 CAPLUS

CN 1-Pentanol, 4-methyl-2-[(5-[(phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-93-7 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-fluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-94-8 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-chlorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-95-9 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-96-0 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(4-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463953-97-1 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(4-bromophenyl)methyl]thio]thiazolo[4,5-

d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-98-2 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-iodophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463953-99-3 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-00-9 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2,5-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-01-0 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2,6-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-02-1 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-03-2 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(3,5-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-04-3 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(3-chloro-2-fluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-05-4 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-chloro-6-fluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-06-5 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(4-bromo-2-fluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463954-07-6 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-bromo-5-fluorophenyl)methyl]thio)thiazolo[4,

, 5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-08-7 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-09-8 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(6-chloro-1,3-benzodioxol-5-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-10-1 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-11-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(3-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463954-12-3 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(4-methoxyphenyl)methyl]thio]thiazolo[4,5-

d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-13-4 CAPLUS

CN 1-Pentanol, 2-[2-amino-5-[[2-fluoro-3-methylphenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-14-5 CAPLUS

CN 1-Pentanol, 2-[2-amino-5-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-15-6 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(2-bromo-5-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-16-7 CAPLUS

CN Benzoic acid, 3-[[[2-amino-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thiomethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-17-8 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[[4-(trifluoromethyl)phenyl]methyl]thio]thiazol  
o[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-18-9 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[[2-(trifluoromethyl)phenyl]methyl]thio]thiazol  
o[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-19-0 CAPLUS

CN Benzonitrile, 4-[[[2-amino-7-[(1R)-1-(hydroxymethyl)-3-  
methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 463954-20-3 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[4-methylphenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-21-4 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[[3-methylphenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463954-22-5 CAPLUS

CN Benzonitrile, 2-[[2-amino-7-[(1R)-1-(hydroxymethyl)-3-

methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-23-6 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[(2-methylphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-24-7 CAPLUS

CN 1-Pentanol, 2-[(2-amino-5-[[3-(trifluoromethyl)phenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-25-8 CAPLUS

CN Benzonitrile, 3-[[[2-amino-7-[(1*R*)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-26-9 CAPLUS


CN 1-Pentanol, 2-[[2-amino-5-[(3-methyl-2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2*R*)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 463954-27-0 CAPLUS

CN Cyclopentanemethanol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 463954-28-1 CAPLUS

CN 1-Hexanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




IT 259101-09-2

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)

RN 259101-09-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-29-2P 463954-31-6P 463954-32-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)

RN 463954-29-2 CAPLUS

CN 1-Pentanol, 2-[[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-

yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 463954-31-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 463954-32-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = H, NR4R5, CONR6R7, 4-7 membered saturated monoazacyclic ring optionally substituted by alkyl or alkyl-OR8; R2 = alkyl, optionally substituted by OR9, NR10R11; R3 = H, alkyl, optionally substituted by OR12, NR13R14; or CR2R3 = cycloalkyl, optionally substituted by OR9 or NR10R11; Ar = (un)substituted Ph; X = a bond, alkyl; R4-R14 = H, alkyl], useful for the treatment or prophylaxis of diseases or conditions in which antagonism of the CX3CR1 receptor is beneficial, particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain, were prepared. Thus, reacting 5-phenylmethylthio-7-chlorothiazolo[4,5-d]pyrimidin-2-ylamine with DL-2-amino-3-methyl-1-butanol in THF afforded 24% ( $\pm$ )-I [R1 = H; R2 = iso-Pr; R3 = H; Ar = Ph; X = a bond]. The exemplified compds. I showed Ki of < 10  $\mu$ M in the SPA-ligand binding assay.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:597993 CAPLUS  
 DOCUMENT NUMBER: 135:166841  
 TITLE: Preparation of thiazolopyrimidines as modulators of chemokine receptor activity  
 INVENTOR(S): Bonnert, Roger; Cage, Peter; Hunt, Fraser; Jewell, Robert; Walters, Iain  
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.  
 SOURCE: PCT Int. Appl., 37 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058907	A1	20010816	WO 2001-SE247	20010207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2359081	A1	20010815	GB 2000-3025	20000211
EP 1257556	A1	20021120	EP 2001-906447	20010207
EP 1257556	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522192	T2	20030722	JP 2001-558056	20010207
AT 269340	E	20040715	AT 2001-906447	20010207
US 2003032642	A1	20030213	US 2002-203580	20020809


US 6958343 B2 20051025  
 PRIORITY APPLN. INFO.: MARPAT 135:166841  
 GB 2000-3025 A 20000211  
 WO 2001-SE247 W 20010207

OTHER SOURCE(S): MARPAT 135:166841  
 IT 333743-41-2P 333743-44-5P 333743-47-8P  
 333744-06-2P 354565-81-4P 354565-82-5P  
 354565-83-6P 354565-84-7P 354565-85-8P  
 354565-86-9P 354565-87-0P 354565-88-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolopyrimidines as modulators of chemokine receptor activity)

RN 333743-41-2 CAPLUS


CN 1-Propanol, 2-[[2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-44-5 CAPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-47-8 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 333744-06-2 CAPLUS  
CN 1-Propanol, 2-[[2-amino-5-[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 354565-81-4 CAPLUS  
CN 1-Propanol, 2-[[2-amino-5-[(1H-benzimidazol-2-ylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 354565-82-5 CAPLUS  
CN 1-Propanol, 2-[[2-amino-5-[(2-furanyl methyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 354565-83-6 CAPLUS  
CN 1-Propanol, 2-[[2-amino-5-[[1-(2-thienyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 354565-84-7 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[[3,5-dimethyl-4-isoxazolyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-85-8 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[[5-methyl-2-furanyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-86-9 CAPLUS

CN Acetamide, N-[4-[[2-amino-7-[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-87-0 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(5-isoxazolylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354565-88-1 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2-furanyl methyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 259101-61-6P 333742-99-7P 333743-71-8P


354565-89-2P 354565-90-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thiazolopyrimidines as modulators of chemokine receptor activity)

RN 259101-61-6 CAPLUS


CN 1-Propanol, 2-[(2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 333742-99-7 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-71-8 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-89-2 CAPLUS


CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 354565-90-5 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R = H, NR<sub>4</sub>R<sub>5</sub> (R<sub>4</sub>, R<sub>5</sub> = H, 4-piperidinyl, cycloalkyl, etc.; NR<sub>4</sub>R<sub>5</sub> = (un)substituted 4-7 membered saturated heterocyclyl); R<sub>1</sub> = alkyl optionally containing one or more atoms selected from O, S, NR<sub>6</sub> (R<sub>6</sub> = H, alkyl, Ph) which terminates in (un)substituted heteroaryl group; R<sub>3</sub>, R<sub>3</sub>' = H, alkyl, cycloalkyl, etc.; NR<sub>2</sub>R<sub>3</sub> = (un)substituted 3-8 membered ring optionally containing one or more atoms selected from O, S, NR<sub>9</sub> (NR<sub>9</sub> = H, alkyl, Ph)], useful in treating an inflammatory diseases such as psoriasis and COPD, were prepared E.g., a multi-step synthesis of I [R = NH<sub>2</sub>; R<sub>1</sub> = 1H-benzimidazol-2-ylmethyl; R<sub>2</sub> = CMe<sub>2</sub>CH<sub>2</sub>OH; R<sub>3</sub> = H] was given. The compds. I were found to have IC<sub>50</sub> of < 10 μM against CXCR2 receptor binding.

REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:265425 CAPLUS


DOCUMENT NUMBER: 134:280857

TITLE: Preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors  
 INVENTOR(S): Willis, Paul Andrew; Bonnert, Roger Victor; Hunt, Simon Fraser; Walters, Iain Alistair Stewart  
 PATENT ASSIGNEE(S): AstraZeneca UK Limited, UK  
 SOURCE: PCT Int. Appl., 85 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025242	A1	20010412	WO 2000-GB3692	20000926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385269	AA	20010412	CA 2000-2385269	20000926
BR 2000014334	A	20020611	BR 2000-14334	20000926
EP 1222195	A1	20020717	EP 2000-960891	20000926
EP 1222195	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511384	T2	20030325	JP 2001-528186	20000926
EE 200200174	A	20030415	EE 2002-174	20000926
NZ 517880	A	20030926	NZ 2000-517880	20000926
EP 1348709	A2	20031001	EP 2003-15019	20000926
EP 1348709	A3	20031119		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 257838	E	20040115	AT 2000-960891	20000926
PT 1222195	T	20040531	PT 2000-960891	20000926
ES 2213043	T3	20040816	ES 2000-960891	20000926
AU 777872	B2	20041104	AU 2000-73049	20000926
NO 2002001448	A	20020522	NO 2002-1448	20020322
ZA 2002002380	A	20030804	ZA 2002-2380	20020325
US 6790850	B1	20040914	US 2002-89571	20020329
HK 1052009	A1	20060113	HK 2003-104330	20030617
US 2004224961	A1	20041111	US 2004-863995	20040609
PRIORITY APPLN. INFO.:			SE 1999-3544	A 19991001
			EP 2000-960891	A3 20000926
			WO 2000-GB3692	W 20000926
			US 2002-89571	A1 20020329

OTHER SOURCE(S): MARPAT 134:280857  
 IT 333742-46-4P 333742-48-6P 333742-63-5P  
 333742-86-2P 333742-87-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)  
 RN 333742-46-4 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-48-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-63-5 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(3-chloro-2-fluorophenyl)methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-86-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[2-hydroxy-1-(methoxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 333742-87-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



IT 333742-56-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-56-6 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(1R)-2-amino-1-methylethyl]amino]-5-[(2,3-difluorophenyl)methyl]thio-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 333742-55-5


CMF C15 H15 F2 N5 O S2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




IT 333742-44-2P 333742-45-3P 333742-47-5P  
333742-49-7P 333742-50-0P 333742-51-1P  
333742-52-2P 333742-53-3P 333742-54-4P  
333742-55-5P 333742-57-7P 333742-58-8P  
333742-59-9P 333742-60-2P 333742-61-3P  
333742-62-4P 333742-64-6P 333742-65-7P  
333742-66-8P 333742-67-9P 333742-68-0P  
333742-69-1P 333742-70-4P 333742-71-5P  
333742-72-6P 333742-73-7P 333742-74-8P  
333742-75-9P 333742-76-0P 333742-77-1P  
333742-78-2P 333742-79-3P 333742-80-6P  
333742-81-7P 333742-82-8P 333742-83-9P  
333742-84-0P 333742-85-1P 333742-88-4P  
333742-89-5P 333742-90-8P 333742-91-9P  
333742-92-0P 333742-93-1P 333742-94-2P  
333742-95-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-44-2 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 333742-45-3 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-47-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]- (9CI) (CA INDEX NAME)




RN 333742-49-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 333742-50-0 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 333742-51-1 CAPLUS  
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[ (2-aminoethyl)amino]-5-[[ (2,3-difluorophenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 333742-52-2 CAPLUS  
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[ (2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)



RN 333742-53-3 CAPLUS  
CN Methanesulfonamide, N-[2-[[5-[[ (2,3-difluorophenyl)methyl]thio]-2,3-dihydro-2-oxothiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 333742-54-4 CAPLUS  
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[ (2,3-difluorophenyl)methyl]thio]-7-[[2-(2-hydroxyethoxy)-1-methylethyl]amino]- (9CI) (CA INDEX NAME)



RN 333742-55-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-amino-1-methylethyl]amino]-5-[[2,3-difluorophenyl)methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-57-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[(1R)-2-[(2-hydroxyethyl)amino]-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-58-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[[[(1R)-2-[(2-hydroxyethyl)amino]-1-methylethyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CRN 333742-57-7  
CMF C17 H19 F2 N5 O2 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 333742-59-9 CAPLUS  
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2,3-difluorophenyl)methyl]thio]-7-  
[[[(1R)-2-(dimethylamino)-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-60-2 CAPLUS  
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-(2-aminoethoxy)-3-  
chlorophenyl)methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 333742-61-3 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-(2-aminoethoxy)-3-chlorophenyl]methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 333742-60-2

CMF C17 H20 Cl N5 O3 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 333742-62-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(3-chloro-4-methoxyphenyl)methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-64-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(3R,4R)-4-hydroxy-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-65-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(3R)-3-pyrrolidinylamino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 333742-66-8 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[[(2-methyl-4-thiazolyl)methyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-67-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[[[(2-methyl-4-thiazolyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 333742-68-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[[[(2-methyl-4-thiazolyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 333742-69-1 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[[[(2-methylphenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 333742-70-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2-furanyl methyl)thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-71-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-amino-1-methylethyl]amino]-5-[[[3-chloro-2-fluorophenyl]methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-72-6 CAPLUS

CN Propanamide, 2-[[5-[[[2,3-difluorophenyl]methyl]thio]-2,3-dihydro-2-oxothiazolo[4,5-d]pyrimidin-7-yl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-73-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(2-thienylmethyl)thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-74-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[[3-methyl-4-(methylsulfonyl)phenyl]methyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-75-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[3-chloro-4-(trifluoromethoxy)phenyl]methyl]thio]-7-[[[(1R)-2-hydroxy-1-

methyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-76-0 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-77-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(2-(dimethylamino)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 333742-78-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2-fluorophenyl)methyl]thio]-7-  
[[[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-79-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-  
methylethyl]amino]-5-[[[(2-methoxyphenyl)methyl]thio]- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 333742-80-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-  
methylethyl]amino]-5-[(2-phenoxyethyl)thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333742-81-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-  
methylethyl]amino]-5-[(3-methylphenyl)methyl]thio]- (9CI) (CA INDEX

NAME)


Absolute stereochemistry.



RN 333742-82-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2-fluoro-3-methylphenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-83-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(3-chlorophenyl)methyl]thio]-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-84-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(3-bromophenyl)methyl]thio]-7-  
[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-85-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[4-(difluoromethoxy)phenyl)methyl]thio]-7-  
[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-88-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2-bromophenyl)methyl]thio]-7-  
[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-89-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-  
[[1R)-2-hydroxy-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




● Na

RN 333742-90-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(3-chloro-2-  
fluorophenyl)methyl]thio]-7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-,  
monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Na

RN 333742-91-9 CAPLUS


CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-  
[[2-hydroxy-1-(methoxymethyl)ethyl]amino]-, monosodium salt (9CI) (CA  
INDEX NAME)



● Na

RN 333742-92-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 333742-93-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[((1R)-2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 333742-94-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[((5-chloro-1,2,3-thiadiazol-4-yl)methyl)thio]-7-[[((1R)-2-hydroxy-1-methylethyl)amino]- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.



RN 333742-95-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[(2,3-difluorophenyl)methyl]thio]-7-[(3R)-3-pyrrolidinylamino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 259100-39-5P 259101-56-9P 259101-61-6P  
259101-68-3P 259101-74-1P 259101-81-0P  
259103-44-1P 259103-45-2P 333742-96-4P  
333742-97-5P 333742-98-6P 333742-99-7P  
333743-00-3P 333743-01-4P 333743-02-5P  
333743-03-6P 333743-04-7P 333743-05-8P  
333743-06-9P 333743-07-0P 333743-08-1P  
333743-09-2P 333743-10-5P 333743-11-6P  
333743-12-7P 333743-13-8P 333743-14-9P  
333743-15-0P 333743-16-1P 333743-17-2P  
333743-18-3P 333743-19-4P 333743-20-7P  
333743-21-8P 333743-22-9P 333743-23-0P  
333743-24-1P 333743-25-2P 333743-30-9P  
333743-32-1P 333743-33-2P 333743-34-3P  
333743-35-4P 333743-36-5P 333743-37-6P  
333743-41-2P 333743-42-3P 333743-43-4P  
333743-44-5P 333743-45-6P 333743-46-7P  
333743-47-8P 333743-48-9P 333743-49-0P  
333743-50-3P 333743-55-8P 333743-56-9P  
333743-57-0P 333743-58-1P 333743-59-2P  
333743-60-5P 333743-71-8P 333743-72-9P  
333743-73-0P 333743-74-1P 333743-75-2P  
333743-76-3P 333743-77-4P 333743-78-5P  
333743-79-6P 333743-80-9P 333743-81-0P

333743-82-1P 333743-83-2P 333743-84-3P  
333743-85-4P 333743-86-5P 333743-87-6P  
333743-88-7P 333743-89-8P 333743-90-1P  
333743-91-2P 333743-92-3P 333743-93-4P  
333743-94-5P 333743-95-6P 333743-97-8P  
333743-98-9P 333743-99-0P 333744-00-6P  
333744-01-7P 333744-02-8P 333744-03-9P  
333744-04-0P 333744-05-1P 333744-06-2P  
333744-07-3P 333744-08-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 259100-39-5 CAPLUS


CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-56-9 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-61-6 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-68-3 CAPLUS

CN Ethanol, 2-[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-74-1 CAPLUS

CN Ethanol, 2-[2-[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 259101-81-0 CAPLUS

CN 1,3-Propanediol, 2-[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-44-1 CAPLUS

CN 1-Propanol, 2-[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259103-45-2 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 333742-96-4 CAPLUS


CN 1-Propanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 333742-97-5 CAPLUS

CN 1-Butanol, 2-[[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-98-6 CAPLUS

CN 1-Butanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333742-99-7 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-00-3 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-01-4 CAPLUS


CN 1-Propanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-02-5 CAPLUS


CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl-, (9CI) (CA INDEX NAME)



RN 333743-03-6 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-04-7 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-05-8 CAPLUS


CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-06-9 CAPLUS

CN Ethanol, 2-[2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 333743-07-0 CAPLUS

CN Ethanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 333743-08-1 CAPLUS

CN 1,3-Propanediol, 2-[[(2-bromo-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-09-2 CAPLUS

CN 1,3-Propanediol, 2-[[(5-[(2,3-difluorophenyl)methyl]thio)-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 333743-10-5 CAPLUS


CN Carbamic acid, [2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 333743-11-6 CAPLUS


CN Carbamic acid, [2-[(2-bromo-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,

,5-d]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 333743-12-7 CAPLUS

CN Carbamic acid, [2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 333743-13-8 CAPLUS

CN Ethanol, 2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-14-9 CAPLUS

CN Ethanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-15-0 CAPLUS

CN Methanesulfonamide, N-[2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 333743-16-1 CAPLUS

CN Methanesulfonamide, N-[2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 333743-17-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl- (9CI) (CA INDEX NAME)




RN 333743-18-3 CAPLUS

CN Ethanol, 2-[2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propoxy- (9CI) (CA INDEX NAME)




RN 333743-19-4 CAPLUS

CN Ethanol, 2-[2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]propoxy- (9CI) (CA INDEX NAME)



RN 333743-20-7 CAPLUS


CN Ethanol, 2-[2-[(5-[(2,3-difluorophenyl)methyl]thio)-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propoxy- (9CI) (CA INDEX NAME)



RN 333743-21-8 CAPLUS

CN Propanamide, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-22-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[(1R)-2-amino-1-methylethyl]-5-[(2,3-difluorophenyl)methyl]thio]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-23-0 CAPLUS

CN Carbamic acid, [(2R)-2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-24-1 CAPLUS

CN Carbamic acid, [(2R)-2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-25-2 CAPLUS

CN Carbamic acid, [(2R)-2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-30-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-32-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[2-amino-5-[[2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-hydroxy-

, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-33-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-34-3 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-35-4 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-36-5 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[(2-bromo-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-37-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-41-2 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-42-3 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-43-4 CAPLUS


CN 1-Propanol, 2-[[2-methoxy-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-44-5 CAPLUS

CN 1,3-Propanediol, 2-[(2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-45-6 CAPLUS

CN 1,3-Propanediol, 2-[(2-bromo-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-46-7 CAPLUS

CN 1,3-Propanediol, 2-[(2-methoxy-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333743-47-8 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 333743-48-9 CAPLUS

CN 1-Propanol, 2-[(2-bromo-5-[(2-methyl-4-thiazolyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 333743-49-0 CAPLUS

CN 1-Propanol, 2-[(2-methoxy-5-[(2-methyl-4-thiazolyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 333743-50-3 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 333743-55-8 CAPLUS  
CN Carbamic acid, [(2R)-2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-56-9 CAPLUS  
CN Carbamic acid, [(2R)-2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-57-0 CAPLUS  
CN Carbamic acid, [(2R)-2-[[2-amino-5-[(3-chloro-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-58-1 CAPLUS

CN Carbamic acid, [(2R)-2-[[2-bromo-5-[(3-chloro-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-59-2 CAPLUS

CN Carbamic acid, [(2R)-2-[[5-[(3-chloro-2-fluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-60-5 CAPLUS

CN Propanamide, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-71-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(1R)-2-hydroxy-1-methylethyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-72-9 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-73-0 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-74-1 CAPLUS

CN 1-Propanol, 2-[[5-[(2-fluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-75-2 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-76-3 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-77-4 CAPLUS

CN 1-Propanol, 2-[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-ylamino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-78-5 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-79-6 CAPLUS

CN 1-Propanol, 2-[(2-bromo-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-80-9 CAPLUS

CN 1-Propanol, 2-[(2-methoxy-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-81-0 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-82-1 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-83-2 CAPLUS

CN 1-Propanol, 2-[(2-methoxy-5-[(3-methylphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-84-3 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2-fluoro-3-methylphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-85-4 CAPLUS

CN 1-Propanol, 2-[(2-bromo-5-[(2-fluoro-3-methylphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-86-5 CAPLUS

CN 1-Propanol, 2-[[5-[[2-fluoro-3-methylphenyl]methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-87-6 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-88-7 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-89-8 CAPLUS

CN 1-Propanol, 2-[[5-[(3-chlorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-90-1 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-91-2 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-92-3 CAPLUS

CN 1-Propanol, 2-[[5-[(3-bromophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-93-4 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[[4-(difluoromethoxy)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-94-5 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[[4-(difluoromethoxy)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333743-95-6 CAPLUS


CN 1-Propanol, 2-[[5-[[[4-(difluoromethoxy)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 333743-97-8 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 333743-98-9 CAPLUS

CN 1-Propanol, 2-[[2-chloro-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 333743-99-0 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 333744-00-6 CAPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 333744-01-7 CAPLUS

CN 1,3-Propanediol, 2-[[2-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 333744-02-8 CAPLUS


CN 1,3-Propanediol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 333744-03-9 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2-bromophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333744-04-0 CAPLUS

CN 1-Propanol, 2-[(2-bromo-5-[(2-bromophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333744-05-1 CAPLUS

CN 1-Propanol, 2-[(5-[(2-bromophenyl)methyl]thio)-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333744-06-2 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 333744-07-3 CAPLUS

CN 1-Propanol, 2-[[2-chloro-5-[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 333744-08-4 CAPLUS

CN 1-Propanol, 2-[[5-[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, etc.], useful in treating a chemokine mediated disease, were prepared E.g., a multi-step synthesis of I [R1 = CH2Ph; R2 = CMe2CH2OH; R3 = H] was described. The compds. I were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:133684 CAPLUS

DOCUMENT NUMBER: 132:166252

TITLE: Preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptor activity

INVENTOR(S): Austin, Rupert; Baxter, Andrew; Bonnert, Roger; Hunt, Fraser; Kinchin, Elizabeth; Willis, Paul

PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra AB

SOURCE: PCT Int. Appl., 155 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000009511	A1	20000224	WO 1999-SE1333	19990803
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2338600 AA 20000224 CA 1999-2338600 19990803  
 AU 9956625 A1 20000306 AU 1999-56625 19990803  
 AU 768004 B2 20031127  
 EP 1104425 A1 20010606 EP 1999-943554 19990803  
 EP 1104425 B1 20030129  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2002522544 T2 20020723 JP 2000-564962 19990803  
 AT 231872 E 20030215 AT 1999-943554 19990803  
 ES 2190246 T3 20030716 ES 1999-943554 19990803  
 US 6806273 B1 20041019 US 2001-403392 20011021  
 SE 1998-2729 A 19980813  
 WO 1999-SE1333 W 19990803  
**PRIORITY APPLN. INFO.:**


**OTHER SOURCE(S):** MARPAT 132:166252

IT 259101-56-9P 259101-61-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity)


RN 259101-56-9 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259101-61-6 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



IT 259100-39-5P 259100-40-8P 259100-44-2P  
 259100-45-3P 259100-66-8P 259100-67-9P  
 259100-68-0P 259100-69-1P 259100-70-4P  
 259100-71-5P 259100-72-6P 259100-73-7P  
 259100-74-8P 259100-75-9P 259100-76-0P  
 259100-77-1P 259100-78-2P 259100-79-3P  
 259100-80-6P 259100-81-7P 259100-82-8P

259101-05-8P 259101-06-9P 259101-07-0P  
259101-08-1P 259101-09-2P 259101-10-5P  
259101-11-6P 259101-12-7P 259101-13-8P  
259101-14-9P 259101-15-0P 259101-17-2P  
259101-18-3P 259101-19-4P 259101-20-7P  
259101-21-8P 259101-22-9P 259101-23-0P  
259101-24-1P 259101-25-2P 259101-26-3P  
259101-27-4P 259101-28-5P 259101-29-6P  
259101-30-9P 259101-31-0P 259101-32-1P  
259101-33-2P 259101-34-3P 259101-35-4P  
259101-36-5P 259101-37-6P 259101-38-7P  
259101-39-8P 259101-40-1P 259101-41-2P  
259101-42-3P 259101-43-4P 259101-44-5P  
259101-45-6P 259101-46-7P 259101-47-8P  
259101-48-9P 259101-49-0P 259101-50-3P  
259101-51-4P 259101-52-5P 259101-53-6P  
259101-54-7P 259101-55-8P 259101-57-0P  
259101-58-1P 259101-59-2P 259101-60-5P  
259101-62-7P 259101-63-8P 259101-65-0P  
259101-66-1P 259101-67-2P 259101-68-3P  
259101-69-4P 259101-70-7P 259101-71-8P  
259101-72-9P 259101-73-0P 259101-74-1P  
259101-75-2P 259101-76-3P 259101-77-4P  
259101-78-5P 259101-80-9P 259101-81-0P  
259101-82-1P 259101-83-2P 259101-84-3P  
259101-85-4P 259101-86-5P 259101-87-6P  
259101-88-7P 259101-89-8P 259101-90-1P  
259101-91-2P 259101-92-3P 259101-93-4P  
259101-94-5P 259101-95-6P 259101-96-7P  
259101-97-8P 259101-98-9P 259101-99-0P  
259102-00-6P 259102-01-7P 259102-10-8P  
259102-11-9P 259102-12-0P 259102-13-1P  
259102-14-2P 259102-15-3P 259102-16-4P  
259102-17-5P 259102-18-6P 259102-19-7P  
259102-20-0P 259102-21-1P 259102-22-2P  
259102-23-3P 259102-24-4P 259102-25-5P  
259102-26-6P 259102-27-7P 259102-28-8P  
259102-29-9P 259102-30-2P 259102-31-3P  
259102-32-4P 259102-33-5P 259102-34-6P  
259102-35-7P 259102-36-8P 259102-37-9P  
259102-38-0P 259102-39-1P 259102-40-4P  
259102-41-5P 259102-42-6P 259102-43-7P  
259102-44-8P 259102-45-9P 259102-46-0P  
259102-47-1P 259102-48-2P 259102-49-3P  
259102-50-6P 259102-51-7P 259102-52-8P  
259102-53-9P 259102-54-0P 259102-57-3P  
259102-58-4P 259102-59-5P 259102-61-9P  
259102-62-0P 259102-63-1P 259102-64-2P  
259102-66-4P 259102-68-6P 259102-69-7P  
259102-70-0P 259102-71-1P 259102-73-3P  
259102-74-4P 259102-75-5P 259102-76-6P  
259102-77-7P 259102-78-8P 259102-79-9P  
259102-80-2P 259102-81-3P 259102-82-4P  
259102-83-5P 259102-84-6P 259102-86-8P  
259102-87-9P 259102-88-0P 259102-89-1P  
259102-90-4P 259102-91-5P 259102-93-7P  
259102-94-8P 259102-95-9P 259102-96-0P  
259102-98-2P 259102-99-3P 259103-00-9P  
259103-01-0P 259103-02-1P 259103-03-2P  
259103-04-3P 259103-05-4P 259103-06-5P  
259103-08-7P 259103-09-8P 259103-10-1P  
259103-11-2P 259103-13-4P 259103-14-5P  
259103-15-6P 259103-16-7P 259103-17-8P


259103-18-9P 259103-19-0P 259103-21-4P  
259103-22-5P 259103-24-7P 259103-25-8P  
259103-26-9P 259103-28-1P 259103-30-5P  
259103-32-7P 259103-33-8P, 259103-34-9P  
259103-35-0P 259104-23-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity)

RN 259100-39-5 CAPLUS

CN 1-Butanol, 2-[(2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259100-40-8 CAPLUS


CN 1-Butanol, 2-[(2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259100-44-2 CAPLUS


CN 1-Butanol, 2-[(2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)




RN 259100-45-3 CAPLUS  
CN Ethanol, 2-[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino-  
(9CI) (CA INDEX NAME)




RN 259100-66-8 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[3-(dimethylamino)propyl]-5-  
(pentylthio)- (9CI) (CA INDEX NAME)




RN 259100-67-9 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(diethylamino)ethyl]-5-  
(pentylthio)- (9CI) (CA INDEX NAME)




RN 259100-68-0 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(dimethylamino)ethyl]-5-  
(pentylthio)- (9CI) (CA INDEX NAME)




RN 259100-69-1 CAPLUS  
CN 1-Propanol, 3-[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino-  
(9CI) (CA INDEX NAME)




RN 259100-70-4 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclohexyl-5-(pentylthio)- (9CI)  
 (CA INDEX NAME)




RN 259100-71-5 CAPLUS  
 CN 1,2-Propanediol, 3-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259100-72-6 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methoxyethyl)-5-(pentylthio)- (9CI) (CA INDEX NAME)




RN 259100-73-7 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(pentylthio)-N7-propyl- (9CI)  
 (CA INDEX NAME)




RN 259100-74-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopentyl-5-(pentylthio)-(9CI) (CA INDEX NAME)




RN 259100-75-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopropyl-5-(pentylthio)-(9CI) (CA INDEX NAME)




RN 259100-76-0 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methylpropyl)-5-(pentylthio)-(9CI) (CA INDEX NAME)



RN 259100-77-1 CAPLUS


CN 2-Propanol, 1-[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino-(9CI) (CA INDEX NAME)



RN 259100-78-2 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-5-(pentylthio)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 259100-79-3 CAPLUS

CN Ethanol, 2-[2-[(2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 259100-80-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methylbutyl)-5-(pentylthio)- (9CI) (CA INDEX NAME)




RN 259100-81-7 CAPLUS

CN 2-Propanol, 1-[(2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259100-82-8 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[ (2-aminophenyl)methyl]-5-(pentylthio)- (9CI) (CA INDEX NAME)




RN 259101-05-8 CAPLUS

CN 1-Propanol, 3-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 259101-06-9 CAPLUS


CN Benzenemethanol,  $\alpha$ -[[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 259101-07-0 CAPLUS


CN Benzenepropanol,  $\beta$ -[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, ( $\beta R$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-08-1 CAPLUS


CN Ethanol, 2-[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-09-2 CAPLUS


CN 1-Pentanol, 2-[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-10-5 CAPLUS


CN 2-Propanol, 1-[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-11-6 CAPLUS  
CN Benzenepropanol,  $\beta$ -[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chloro- (9CI) (CA INDEX NAME)




RN 259101-12-7 CAPLUS  
CN 1,2-Propanediol, 3-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-13-8 CAPLUS  
CN Ethanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 259101-14-9 CAPLUS  
CN 3-Pyrrolidinol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-15-0 CAPLUS

CN 3-Piperidinol, 1-[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 259101-17-2 CAPLUS

CN 4-Piperidinol, 1-[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 259101-18-3 CAPLUS

CN 1-Propanol, 3-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl- (9CI) (CA INDEX NAME)




RN 259101-19-4 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-20-7 CAPLUS

CN Benzenemethanol,  $\alpha$ -[[2-amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl- (9CI) (CA INDEX NAME)




RN 259101-21-8 CAPLUS

CN 1-Butanol, 4-[[2-amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-22-9 CAPLUS

CN 1-Hexanol, 6-[[2-amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-23-0 CAPLUS


CN Cyclohexanol, 4-[[2-amino-5-[[3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-24-1 CAPLUS


CN Benzenepropanol,  $\beta$ -[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, ( $\beta$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-25-2 CAPLUS

CN 1-Phenyl-2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-26-3 CAPLUS


CN Ethanol, 2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-27-4 CAPLUS


CN 1-Pentanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-28-5 CAPLUS

CN 2-Propanol, 1-amino-3-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-29-6 CAPLUS

CN 2-Propanol, 1-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-30-9 CAPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 259101-31-0 CAPLUS

CN Benzenepropanol,  $\beta$ -[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chloro- (9CI) (CA INDEX NAME)




RN 259101-32-1 CAPLUS

CN 1,2-Propanediol, 3-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-33-2 CAPLUS

CN Ethanol, 2-[[2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]amino]- (9CI) (CA INDEX NAME)




RN 259101-34-3 CAPLUS


CN 1-Propanol, 3-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-35-4 CAPLUS  
 CN Benzenepropanol,  $\gamma$ -[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-3,4-dichloro- (9CI) (CA INDEX NAME)



RN 259101-36-5 CAPLUS  
 CN 2-Propanol, 1-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-37-6 CAPLUS  
 CN Ethanol, 2-[2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 259101-38-7 CAPLUS


CN 1-Pentanol, 5-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-39-8 CAPLUS


CN 1-Butanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-(methylthio)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-40-1 CAPLUS

CN Ethanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]butylamino]- (9CI) (CA INDEX NAME)




RN 259101-41-2 CAPLUS


CN Ethanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 259101-42-3 CAPLUS  
CN Ethanol, 2,2'-[ [2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]imino]bis- (9CI) (CA INDEX NAME)




RN 259101-43-4 CAPLUS  
CN Phenol, 2-[ [2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl](2-hydroxyethyl)amino]methyl- (9CI) (CA INDEX NAME)



RN 259101-44-5 CAPLUS  
CN 1-Propanol, 3-[ [2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl](2-hydroxyethyl)amino]- (9CI) (CA INDEX NAME)




RN 259101-45-6 CAPLUS  
CN 3-Pyrrolidinol, 1-[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 259101-46-7 CAPLUS


CN L-Proline, 1-[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-hydroxy-, phenylmethyl ester, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-47-8 CAPLUS

CN 3-Piperidinemethanol, 1-[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 259101-48-9 CAPLUS


CN 3-Piperidinol, 1-[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 259101-49-0 CAPLUS


CN 2-Pyrrolidinemethanol, 1-[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-50-3 CAPLUS


CN 4-Piperidinol, 1-[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 259101-51-4 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-52-5 CAPLUS

CN 1-Butanol, 2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-53-6 CAPLUS

CN 1-Butanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-54-7 CAPLUS


CN 1,3-Propanediol, 2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-

d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-55-8 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(3-phenoxyphenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-57-0 CAPLUS

CN 2-Propanol, 1-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259101-58-1 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[(2,3-difluorophenyl)methyl]thio]-N7-(2-fluoroethyl)- (9CI) (CA INDEX NAME)



RN 259101-59-2 CAPLUS

CN Cyclopentanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-60-5 CAPLUS


CN Cyclopentanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-62-7 CAPLUS

CN 1-Propanol, 2-methyl-2-[[2-(methylamino)-5-(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-63-8 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259101-65-0 CAPLUS


CN 1-Butanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-66-1 CAPLUS


CN Cyclohexanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-67-2 CAPLUS

CN 1-Propanol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-68-3 CAPLUS


CN Ethanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259101-69-4 CAPLUS


CN 1-Pentanol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-70-7 CAPLUS


CN 2-Propanol, 1-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-71-8 CAPLUS  
 CN 1,3-Propanediol, 2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-72-9 CAPLUS  
 CN Cyclohexanol, 1-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl- (9CI) (CA INDEX NAME)



RN 259101-73-0 CAPLUS  
 CN Ethanol, 2-[(2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino)ethyl]amino]- (9CI) (CA INDEX NAME)




RN 259101-74-1 CAPLUS  
CN Ethanol, 2-[2-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy- (9CI) (CA INDEX NAME)




RN 259101-75-2 CAPLUS  
CN Benzenemethanol,  $\alpha$ -[(1R)-1-[(2-amino-5-[(2,3-difluorophenyl)methyl]thio)thiazolo[4,5-d]pyrimidin-7-yl)methylamino]ethyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259101-76-3 CAPLUS  
CN 4-Piperidinol, 1-[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl- (9CI) (CA INDEX NAME)




RN 259101-77-4 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[(2,3-difluorophenyl)methyl]thio]-N7-ethyl- (9CI) (CA INDEX NAME)



RN 259101-78-5 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[[(2,3-difluorophenyl)methyl]thio]-N7-2-propenyl- (9CI) (CA INDEX NAME)



RN 259101-80-9 CAPLUS


CN 1,3-Propanediol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-phenyl-, (1S,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259101-81-0 CAPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-82-1 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[[(2,3-difluorophenyl)methyl]thio]-N7-(2-methoxy-1-methylethyl)- (9CI) (CA INDEX NAME)




RN 259101-83-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopropyl-5-[[[(2,3-difluorophenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 259101-84-3 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[[(2,3-difluorophenyl)methyl]thio]-N7-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 259101-85-4 CAPLUS


CN L-Serine, N-[5-[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 259101-86-5 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259101-87-6 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-88-7 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[[2-(1H-indol-3-yl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-89-8 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-90-1 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(2,2-diphenylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-91-2 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259101-92-3 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[[[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259101-93-4 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259101-94-5 CAPLUS

CN 1-Propanol, 2-[[5-[[2,3-difluorophenyl]methyl]thio]-2-[(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259101-95-6 CAPLUS

CN 1-Propanol, 2-[[5-[[2,3-difluorophenyl]methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-96-7 CAPLUS

CN Acetamide, 2-[[5-[[2,3-difluorophenyl]methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 259101-97-8 CAPLUS

CN 1-Propanol, 2-[[2-[(2-(4-aminophenyl)ethyl)amino]-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-98-9 CAPLUS

CN 1-Propanol, 2-[[5-[(2,3-difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259101-99-0 CAPLUS

CN 1-Propanol, 2-[[2-(cyclopropylamino)-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-00-6 CAPLUS

CN 1-Pentanol, 2-[[5-[[2,3-difluorophenyl]methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-01-7 CAPLUS

CN 1-Propanol, 2-[[5-[[2,3-difluorophenyl]methyl]thio]-2-[(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-10-8 CAPLUS

CN 1-Propanol, 2-[[2-(cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-11-9 CAPLUS

CN 1-Propanol, 2-[(2-[(1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-12-0 CAPLUS

CN Alanine, N-[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 259102-13-1 CAPLUS


CN Cyclohexanol, 4-[(7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-14-2 CAPLUS  
CN 1-Propanol, 2-methyl-2-[2-[(4-phenylbutyl)amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)




RN 259102-15-3 CAPLUS  
CN 1-Propanol, 2-methyl-2-[5-[(phenylmethyl)thio]-2-[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-16-4 CAPLUS  
CN 1-Propanol, 2-methyl-2-[2-[(1-methylethyl)amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)




RN 259102-17-5 CAPLUS  
CN 1-Propanol, 2-[(2-[(2-(4-aminophenyl)ethyl]amino)-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)



RN 259102-18-6 CAPLUS

CN L-Valine, N-[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-, ethyl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 259102-19-7 CAPLUS


CN Pentanamide, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-4-methyl-, (2S)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-20-0 CAPLUS

CN 1-Propanol, 2-methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)




RN 259102-21-1 CAPLUS

CN 1-Propanol, 2-[[2-[(4-aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-22-2 CAPLUS

CN 1-Propanol, 2-methyl-2-[[5-[(phenylmethyl)thio]-2-[(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino- (9CI) (CA INDEX NAME)




RN 259102-23-3 CAPLUS

CN 1-Propanol, 2-[[2-[(2-fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259102-24-4 CAPLUS


CN 1-Propanol, 2-methyl-2-[[2-[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-25-5 CAPLUS


CN Benzenemethanol,  $\alpha$ -[(1*S*)-1-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-26-6 CAPLUS


CN 1-Propanol, 2-methyl-2-[[5-[(phenylmethyl)thio]-2-[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-27-7 CAPLUS


CN 1-Propanol, 2-methyl-2-[[2-[(1*R*,2*S*)-2-phenylcyclopropyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-28-8 CAPLUS

CN 1-Propanol, 2-[2-[(2-(1H-indol-3-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-29-9 CAPLUS

CN 1-Propanol, 2-[2-[(1,1-dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-30-2 CAPLUS


CN 1-Propanol, 2-methyl-2-[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-31-3 CAPLUS  
 CN 1-Propanol, 2-methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-32-4 CAPLUS  
 CN 1-Propanol, 2-[[2-[(2-aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259102-33-5 CAPLUS  
 CN 1,3-Propanediol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-34-6 CAPLUS  
 CN 1-Propanol, 2-[{2-[{2-(ethylthio)ethyl]amino}-5-  
      [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
      (CA INDEX NAME)




RN 259102-35-7 CAPLUS  
 CN 1-Butanol, 2-[{7-[{2-hydroxy-1,1-dimethylethyl}amino]-5-  
      [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-3,3-dimethyl-,  
      (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-36-8 CAPLUS  
 CN Benzenemethanol,  $\alpha$ -[{(1R)-1-[{7-[{2-hydroxy-1,1-dimethylethyl}amino]-  
      5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl}amino]-2-methoxyethyl}-  
      , (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 259102-37-9 CAPLUS  
 CN 1-Propanol, 2-[{2-(ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-  
      d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-38-0 CAPLUS  
 CN 1-Propanol, 2-[2-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-39-1 CAPLUS  
 CN 1-Propanol, 2-methyl-2-[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-40-4 CAPLUS  
 CN 1-Propanol, 2-[2-[(4-methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-41-5 CAPLUS  
CN 1-Propanol, 2-[(2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259102-42-6 CAPLUS  
CN 1-Propanol, 2-[(2-[(2-(1H-imidazol-4-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-43-7 CAPLUS  
CN 1-Propanol, 2-[(2-[(diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259102-44-8 CAPLUS  
CN 1-Butanol, 2-[(7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-45-9 CAPLUS

CN 1-Propanol, 2-[2-[(2,2-diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
(CA INDEX NAME)



RN 259102-46-0 CAPLUS


CN 1-Butanol, 4-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-47-1 CAPLUS


CN Cyclohexanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (1S,2S)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 259102-48-2 CAPLUS

CN 1-Propanol, 2-[{2-[{2-hydroxy-1-methylethyl}amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl}amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-49-3 CAPLUS

CN 1-Propanol, 2-[{2-[{2-(2-hydroxyethoxy)ethyl}amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl}amino]-2-methyl- (9CI)  
(CA INDEX NAME)




RN 259102-50-6 CAPLUS


CN 1-Pentanol, 2-[{7-[{2-hydroxy-1,1-dimethylethyl}amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl}amino]- (9CI) (CA INDEX NAME)



RN 259102-51-7 CAPLUS  
 CN Acetamide, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-  
 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX  
 NAME)




RN 259102-52-8 CAPLUS  
 CN 1-Propanol, 2-[[2-[(2-(4-fluorophenyl)ethyl)amino]-5-  
 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI)  
 (CA INDEX NAME)




RN 259102-53-9 CAPLUS  
 CN Cyclohexanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-  
 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (1R,2S)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-54-0 CAPLUS  
 CN Benzenemethanol,  $\alpha$ -[(1R)-1-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-  
 [(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-,  
 ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-57-3 CAPLUS  
 CN 1-Propanol, 2-[(2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-58-4 CAPLUS  
 CN 1-Pentanol, 4-methyl-2-[(2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-59-5 CAPLUS  
 CN L-Serine, N-[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-61-9 CAPLUS

CN 1-Butanol, 2-[[5-[(phenylmethyl)thio]-2-[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-62-0 CAPLUS


CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-63-1 CAPLUS

CN 1-Pentanol, 4-methyl-2-[[5-[(phenylmethyl)thio]-2-[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259102-64-2 CAPLUS


CN L-Serine, N-[5-[(phenylmethyl)thio]-2-[[[tetrahydro-2-furanyl]methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-66-4 CAPLUS

CN 1-Propanol, 2-[[2-[(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-68-6 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[7-[[1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]amino]benzenesulfonamide (9CI) (CA INDEX NAME)



RN 259102-69-7 CAPLUS


CN Benzenesulfonamide, 4-[2-[(7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 259102-70-0 CAPLUS


CN Benzenesulfonamide, 4-[2-[(7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-71-1 CAPLUS


CN Benzenesulfonamide, 4-[2-[(7-[(2-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 259102-73-3 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-ethyl-N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 259102-74-4 CAPLUS  
 CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-N7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 259102-75-5 CAPLUS  
 CN 1-Butanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-76-6 CAPLUS  
 CN 1-Propanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)


NAME)



RN 259102-77-7 CAPLUS


CN 1-Pentanol, 2-[[2-[(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




RN 259102-78-8 CAPLUS

CN 2-Propanol, 1-[[2-[(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-79-9 CAPLUS

CN 1-Pentanol, 2-[[2-[(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-80-2 CAPLUS

CN 4-Piperidinol, 1-[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 259102-81-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)




RN 259102-82-4 CAPLUS


CN Ethanol, 2-[ethyl[2-[(2-(1H-imidazol-4-yl)ethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259102-83-5 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-[2-(1H-imidazol-4-yl)ethyl]-N7,N7-dimethyl-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 259102-84-6 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(diethylamino)ethyl]-N7-ethyl-N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 259102-86-8 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-(2-phenoxyethyl)-5-[(phenylmethyl)thio]-N7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 259102-87-9 CAPLUS  
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-(2-phenoxyethyl)-N7-[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 259102-88-0 CAPLUS

CN 1-Propanol, 2-methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-89-1 CAPLUS


CN 1-Propanol, 2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-90-4 CAPLUS


CN 1-Pentanol, 4-methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259102-91-5 CAPLUS

CN 4-Piperidinol, 1-[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-4-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 259102-93-7 CAPLUS

CN 1-Butanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-94-8 CAPLUS


CN 1-Propanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-95-9 CAPLUS

CN 1-Pentanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259102-96-0 CAPLUS

CN L-Serine, N-[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259102-98-2 CAPLUS

CN 1-Pentanol, 2-[[2-[[1-(hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 259102-99-3 CAPLUS


CN L-Serine, N-[2-[[1-(hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259103-00-9 CAPLUS

CN 1-Pentanol, 2-[[7-[cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-01-0 CAPLUS

CN Ethanol, 2-[2-[[7-(ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)




RN 259103-02-1 CAPLUS

CN Ethanol, 2-[2-[[7-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]- (9CI) (CA INDEX NAME)



RN 259103-03-2 CAPLUS


CN 1-Butanol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259103-04-3 CAPLUS


CN 1-Pentanol, 2-[[2-[(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259103-05-4 CAPLUS

CN Ethanol, 2-[cyclohexyl[2-[(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-06-5 CAPLUS


CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-08-7 CAPLUS  
 CN Acetamide, N-[2-[[7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 259103-09-8 CAPLUS  
 CN Acetamide, N-[2-[[7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 259103-10-1 CAPLUS  
 CN Acetamide, N-[2-[[7-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 259103-11-2 CAPLUS  
 CN Acetamide, N-[2-[[7-[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259103-13-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methoxyethyl)-5-[ (phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 259103-14-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-ethoxyethyl)-5-[ (phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 259103-15-6 CAPLUS


CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2,2-dimethylpropyl)-5-[ (phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)



RN 259103-16-7 CAPLUS


CN 1-Pentanol, 4-methyl-2-[5-[ (phenylmethyl)thio]-2-[ [2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259103-17-8 CAPLUS

CN 2-Propanol, 1-[[5-[(phenylmethyl)thio]-2-[(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-18-9 CAPLUS

CN 1-Butanol, 2-[[5-[(phenylmethyl)thio]-2-[(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259103-19-0 CAPLUS


CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-[(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259103-21-4 CAPLUS


CN 1-Pentanol, 2-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-22-5 CAPLUS


CN 3-Piperidinecarboxamide, N,N-diethyl-1-[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]- (9CI) (CA INDEX NAME)



RN 259103-24-7 CAPLUS


CN 1-Pentanol, 2-[2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 259103-25-8 CAPLUS

CN 1-Butanol, 2-[2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 259103-26-9 CAPLUS

CN 1-Propanol, 2-[(2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl)amino]- (9CI) (CA INDEX NAME)




RN 259103-28-1 CAPLUS

CN Acetamide, 2-[(7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl)amino]- (9CI) (CA INDEX NAME)




RN 259103-30-5 CAPLUS


CN 1-Piperazinesulfonamide, 4-[(1-[(4-methylcyclohexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl)-3-azetidinyl]- (9CI) (CA INDEX NAME)




RN 259103-32-7 CAPLUS  
CN 1-Propanol, 3-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)



RN 259103-33-8 CAPLUS  
CN 1-Propanol, 2-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)




RN 259103-34-9 CAPLUS  
CN 1-Propanol, 2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX  
NAME)




RN 259103-35-0 CAPLUS  
CN 1-Pentanol, 4-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-  
[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 259104-23-9 CAPLUS

CN 1-Butanol, 4-[[2-amino-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)




IT 259103-44-1P 259103-45-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity)


RN 259103-44-1 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 259103-45-2 CAPLUS

CN 1-Propanol, 2-[[2-bromo-5-[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



GI



AB The title compds. [I; R1 = H, NR3R4 (wherein R3, R4 = H, 4-piperidinyl, alkyl, etc.; NR3R4 = (un)substituted 4-7 membered saturated heterocyclic ring); X = OH, NR13R14 (R13, R14 = H, 4-piperidinyl, etc.; NR13R14 = (un)substituted 4-7 membered saturated heterocyclic ring); R2 = alkyl, alkenyl optionally substituted by (un)substituted Ph or PhO], useful for treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor such as an inflammatory disease (e.g. psoriasis), were prepared Thus, treating 2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one with POCl3 and N,N-dimethylaniline followed by reacting the resulting 7-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine with (R)-2-amino-1-butanol in THF afforded the title thiazolopyrimidine (2R)-II. Exemplified compds. I were found to have IC50 of < 10  $\mu$ M against hrCXCR2 binding.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1996:243961 CAPLUS

DOCUMENT NUMBER: 125:10744

TITLE: New synthesis of substituted 4-aminoquinazolines and their hetero analogs

AUTHOR(S): Gewald, K.; Schaefer, H.; Eckert, K.; Jeschke, T.

CORPORATE SOURCE: Inst. Org. Chem., Technischen Univ. Dresden, Dresden, Germany

SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung (1996), 338(3), 206-13

CODEN: JPCCEM; ISSN: 0941-1216

PUBLISHER: Barth

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 125:10744


IT 146381-64-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted aminoquinazolines and their hetero analogs)

RN 146381-64-8 CAPLUS

CN Acetic acid, [[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




IT 146381-65-9P 177355-96-3P 177355-97-4P  
177355-98-5P 177356-01-3P 177356-02-4P  
177356-03-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of substituted aminoquinazolines and their hetero analogs)


RN 146381-65-9 CAPLUS

CN Acetic acid, [[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]- (9CI) (CA INDEX NAME)




RN 177355-96-3 CAPLUS

CN Acetamide, 2-[[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 177355-97-4 CAPLUS


CN Piperidine, 1-[[[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]acetyl]- (9CI) (CA INDEX NAME)



RN 177355-98-5 CAPLUS


CN Morpholine, 4-[[[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-

yl]thio]acetyl]- (9CI) (CA INDEX NAME)




RN 177356-01-3 CAPLUS

CN Acetamide, 2-[[7-amino-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 177356-02-4 CAPLUS

CN Piperidine, 1-[[7-amino-2-(1-piperidinyl)thiazolo[4,5-d]pyrimidin-5-yl]thio]acetyl]- (9CI) (CA INDEX NAME)




RN 177356-03-5 CAPLUS

CN Morpholine, 4-[[7-amino-2-(4-morpholinyl)thiazolo[4,5-d]pyrimidin-5-yl]thio]acetyl]- (9CI) (CA INDEX NAME)



GI



AB N-(chloroacetyl)anthranilonitrile reacted with KSCN in the presence of EtOH to the quinazolinylthioacetic acid ester I (R = SCH<sub>2</sub>CO<sub>2</sub>Et, R<sub>1</sub> = H). In the presence of H<sub>2</sub>O or primary amine the derivs. I (R = SCH<sub>2</sub>CO<sub>2</sub>H, SCH<sub>2</sub>CONHR<sub>2</sub>) were obtained. Diaminoquinazolines I [R = NR<sub>2</sub>R<sub>3</sub>; R<sub>1</sub>, R<sub>2</sub> = CH<sub>2</sub>Ph, NH<sub>2</sub>, R<sub>3</sub> = H; R<sub>1</sub> = H, R<sub>2</sub>R<sub>3</sub> = -(CH<sub>2</sub>)<sub>5</sub>-] arose if vigorous reaction conditions are employed. Starting from 2-(chloroacetyl)aminocyclopent-1-enecarbonitrile the pyrimidines II [R = SCH<sub>2</sub>COR<sub>4</sub>; R<sub>4</sub> = OH, OMe, NHCH<sub>2</sub>Ph, HNNH<sub>2</sub>, NH(CH<sub>2</sub>)<sub>2</sub>NET<sub>2</sub>] were formed with KSCN. Analogously, pyrimidylselenoacetic acid derivs. were prepared with KSeCN. N-chloroacetyl derivs. of 5-membered heterocycles with enaminonitrile structure reacted with KSCN to yield thieno[2,3-d]-, thiazolo[4,5-d]-, pyrrolo[2,3-d]-, furo[2,3-d], and pyrazolo[4,3-d]pyrimidines.

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1993:147575 CAPLUS

DOCUMENT NUMBER: 118:147575

TITLE: Preparation of (arenopyrimidinylthio)acetates and analogs

INVENTOR(S): Gewald, Karl; Schaefer, Harry; Jeschke, Torsten; Eckert, Katrin; Faust, Gottfried; Laban, Gunter

PATENT ASSIGNEE(S): Arzneimittelwerk Dresden GmbH, Germany

SOURCE: Ger. Offen., 7 pp.

CODEN: GWXXBX


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4119767	A1	19921217	DE 1991-4119767	19910615
PRIORITY APPLN. INFO.:			DE 1991-4119767	19910615
OTHER SOURCE(S):	CASREACT 118:147575; MARPAT 118:147575			
IT 146381-64-8P	146381-65-9P			
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, method for)				
RN 146381-64-8	CAPLUS			
CN Acetic acid, [[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]-, ethyl ester (9CI)	(CA INDEX NAME)			




RN 146381-65-9 CAPLUS

CN Acetic acid, [[7-amino-2-(methylthio)thiazolo[4,5-d]pyrimidin-5-yl]thio]-




GI



AB Title compds. [I; A = atoms to complete a (substituted) aromatic or heterocyclic ring; R1 = NH2, OH; R2 = OH, alkoxy; X = Se, S; dashed lined = optional bond] were prepared by cyclocondensation of acetamidocyclic compds. II (R = halo, Y = cyano, alkoxy carbonyl) with SCN- or SeCN- in the presence of R2H. Thus, 2-(NC)C6H4NHCOCH2Cl was refluxed 3 h with KSCN in EtOH to give 69% title compound III.

L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1955:84542 CAPLUS  
 DOCUMENT NUMBER: 49:84542  
 ORIGINAL REFERENCE NO.: 49:15981g-i,15982a-b  
 TITLE: 2-Amino-5,7-disubstituted thiazolo(4,5-d)pyrimidines  
 PATENT ASSIGNEE(S): Wellcome Foundation Ltd.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
IT	GB 713652		19540818	GB 1951-13173	19510604
IT	30162-03-9, Thiazolo[4,5-d]pyrimidine, 2,7-diamino-5-(methylthio)- (preparation of)				
RN	30162-03-9 CAPLUS				
CN	Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(methylthio)- (9CI) (CA INDEX NAME)				



GI For diagram(s), see printed CA Issue.

AB The preparation of I is covered, in which R is H, Me, NH<sub>2</sub>, OH, or ZS (Z = alkyl group containing 1 to 5 C atoms) and R' is NH<sub>2</sub>, OH, or Me with either R or R' being OH or NH<sub>2</sub>. To 2,4-diamino-6-methylpyrimidine (12.4 g.) and 40 g. KSCN in 200 ml. 96% AcOH was added in subdued light with ice-cooling and stirring, 6 ml. Br in 100 ml. HOAc, stirred an addnl. 40 min., the temperature was raised to 70°, 50 ml. of H<sub>2</sub>O added and light admitted to increase the polymerization rate of the excess thiocyanogen (II). The insol. orange polymer of II was filtered from the hot solution, the filtrate cooled in an ice-bath and made alkaline by the addition of concentrated NH<sub>4</sub>OH.

The

resulting yellow solid was let stand overnight at 5°. and filtered to yield 10.1 g. 2,5-diamino-7-methylthiazolo-(4,5-d)pyrimidine hydrate, m. 249-50° (from 95% EtOH). In an analogous manner, the following I were prepared from the appropriate pyrimidine (R, R', m.p. given): NH<sub>2</sub>, Me, >300°; NH<sub>2</sub>, NH<sub>2</sub>, >300°; OH, OH, >310°; NH<sub>2</sub>, MeS, 208-9°; OH, NH<sub>2</sub>, >310°; NH<sub>2</sub>, H, 245-7°. Most of these compds. are monohydrates; the H<sub>2</sub>O of hydration is lost at 140° in vacuo, but is regained upon exposure to air. These compds. are growth-inhibitors for microorganisms, being particularly active for Lactobacillus casei, Bacillus subtilis, Salmonella typhosa, Staphylococcus aureus, and Escherichia coli.

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1952:23490 CAPLUS

DOCUMENT NUMBER: 46:23490

ORIGINAL REFERENCE NO.: 46:4008c-i

TITLE: Condensed pyrimidine systems. VI. Some 2-aminothiazolo[4, 5-d]-pyrimidines

CORPORATE SOURCE: Wellcome Research Labs., Tuckahoe, NY

SOURCE: Journal of the American Chemical Society (1951), 73, 4226-8

CODEN: JACSAT; ISSN: 0002-7863


DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

IT 30162-03-9, Thiazolo[4,5-d]pyrimidine, 2,7-diamino-5-(methylthio)-(preparation of)

RN 30162-03-9 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(methylthio)-(9CI) (CA INDEX NAME)



AB cf. C.A. 45, 8536h. Thiocyanation in the 5-position occurs readily with pyrimidines bearing at least 2 OH or NH<sub>2</sub> groups in positions 2, 4, and 6. The 4-amino-5-thiocyanopyrimidines are readily cyclized to 2-aminothiazolo[4, 5-d]pyrimidines. An alternate synthesis of thiazolo[4,

5-d]pyrimidines bearing nonfunctional substituents in the 2- and 4-position was also developed. Two general methods of preparation of thiazolopyrimidines were used: Method A. 2, 4-Diamino-6-methylpyrimidine (12.4 g.) and 40 g. KSCN in 200 cc. 96% AcOH treated with 6 cc. Br in 100 cc. AcOH during 30 min. (ice bath and darkened room), the ice bath removed, the mixture stirred 40 min., heated to 70°, diluted with 50 cc. hot water (lights on), filtered hot, the filtrate (ice bath) slowly made alkaline with concentrated NH4OH, and the product allowed to stand overnight at

5° yielded 10.1 g. 2, 5-diamino-7-methylthiazolo-[4, 5-d]pyrimidine-H2O, m. 249-50° (from EtOH). The hydrates lose water of crystallization after 3 hrs. at 140° in vacuo, but tend to regain it on exposure to air. Method B. POCl3 (100 cc.) and 30 g. 2-ethylmercapto-4-hydroxy-6-methylpyrimidine heated 1 hr. on the steam bath, most of the POCl3 removed in vacuo, 200 g. ice and 200 cc. Et2O added to the oil, then NH4OH to pH 8-9, the Et2O layer added to 100 cc. EtOH containing 17 g. KSCN, the Et2O removed, 100 cc. PhMe added, the solution concentrated to 75°, 100 cc. xylene added, the mixture refluxed 2 hrs., filtered warm, and 20 cc. concentrated NH4OH added to the filtrate yielded 18 g.

2-ethylmercapto-6-methyl-4-thioureidopyrimidine (I), m. 235-6°. Powdered I (4.4 g.) in 20 cc. CHCl3 treated during 15 min. with 1 cc. Br in 10 cc. CHCl3 (temperature below 30°), the solution evaporated to dryness on the steam bath, the residue treated 10 min. with 2 g. Na2S2O4 in 50 cc. water, and the oil treated with excess NH3 yielded 4 g. 2-amino-5-ethylmercapto-7-methylthiazolo[4, 5-d]pyrimidine, m. 187-9° (from 50% EtOH). 2-Amino-4-hydroxy-6-phenylpyrimidine (4.7 g.) and 6.2 g. NaSCN, in 200 cc. warm MeOH saturated with NaBr and 50 cc. AcOH, treated at 5° during 20 min. with 1.8 cc. Br in 50 cc. AcOH, the mixture stirred 1 hr. without an ice bath, heated to boiling, 20 cc. hot water added, the hot solution filtered, brought to pH 6 with 10% NH3, and most of the alc. removed in vacuo yielded 4.1 g. 2-amino-4-hydroxy-6-phenyl-5-thiocyanopyrimidine (II), m. 287-9° (decomposition). II (0.5 g.) in 30 cc. 10% NaOH let stand overnight, diluted to 200 cc., filtered, and the filtrate brought to pH 6 with 10% AcOH yielded 100% bis(2-amino-4-hydroxy-6-phenyl-5-pyrimidyl) disulfide, pale yellow crystalline precipitate, m. above 300°. For the 5-R-7-R'-disubstituted 2-aminothiazolo[4, 5-d]pyrimidines (prepared by Method A), R, R' m.p., yield (%), and recrystn. solvent are: NH2, Me, 249-50°, 52, EtOH; Me, NH2, above 300°, 63, EtOH; NH2, NH2, above 300°, 75, water; OH, OH, above 310°, 45, water; MeS, NH2, 208-9°, 79, 50% EtOH; NH2, OH, above 310°, 72, water; H, NH2, 245-7°, 54, water. Biologically the compds. show several resemblances to other purine analogs.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	72.00	239.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -10.50 -10.50

STN INTERNATIONAL LOGOFF AT 09:41:50 ON 23 SEP 2006